David Bartolec has significantly increased his ownership in Brookmount Explorations Inc, now holding 10.25% of the company's shares. This move is noteworthy as it may indicate Bartolec's confidence in the future of the mining industry, particularly in the sector focused on nonmetallic minerals. The increase in stake could also lead to heightened scrutiny of Brookmount's operations.
Background
Bartolec David John is an individual investor, and his recent SEC filing indicates a growing interest in Brookmount Explorations Inc, a company engaged in the mining and quarrying of nonmetallic minerals. The company is incorporated in Nevada and has its principal executive office located in Vancouver, British Columbia. The filing was made on November 10, 2026, and is an amendment to a previous filing.
What the Filing Says
According to the filing, Bartolec now beneficially owns 369,050,320 shares of Brookmount Explorations Inc, which constitutes 10.25% of the company. The filing also states, "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired... for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." This suggests that Bartolec does not intend to influence the management or direction of Brookmount.
Impact
This increase in ownership may affect various stakeholders within Brookmount Explorations Inc, including its management and other shareholders. Given Bartolec's significant stake, his actions and opinions could carry more weight in future company decisions, even if he does not plan to influence control directly.
What's Next
The filing does not say what happens next.
Read Next
Mizuho Financial Group Takes 5.6% Stake in GalaxyEdge Corp
Helikon Investments Takes 5.1% Stake in Super Group Ltd
Mizuho Financial Group Discloses 6.2% Stake in Bold Eagle
Japan Post Holdings Amends Schedule 13G, Holds 10.13% in Aflac
Ashish Arora Amends Schedule 13G for Cricut Stake
Bank of Montreal Increases Stake in Akari Therapeutics



